Sichuan Biokin Pharmaceutical
 | |
Native name | 四川百利天恒药业股份有限公司 |
|---|---|
| Type | Public |
| SSE: 688506 | |
| Industry | Biopharmaceutical |
| Founded | August 23, 1996 |
| Founder |
|
| Headquarters | Chengdu, Sichuan, China |
Key people | Zhu Yi (Chairman & CEO) |
| Revenue |  CN¥5.82 billion (2024) |
| CN¥3.71 billion (2024) | |
| Total assets | CN¥7.14 billion (2024) |
| Total equity | CN¥3.89 billion (2024) |
| Website | www |
Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin; Chinese: 百利天恒; pinyin: Bǎilì tiānhéng) is a publicly listed Chinese biopharmaceutical company that is headquartered in Chengdu, Sichuan.
History
[edit]Biokin started out in 1996 as a producer of complex generic drugs and traditional Chinese medicines.[1]
In 2010 Biokin pivoted towards the innovative drug business, using its revenue from established products to fund research into specialized cancer therapies.[1]
In early 2023, Biokin held its initial public offering and became a listed company on the Shanghai Stock Exchange STAR Market.[1]
In December 2023 Biokin's wholly owned subsidiary SystImmune and Bristol Myers Squibb came to a deal that would pay SystImmune up to $8.4 billion for rights to co-develop and sell an experimental drug for lung and breast cancers. The agreement included an $800 million upfront payment to and as much as $500 million in contingent near-term payments.[1][2]
In July 2024, Biokin filed for a secondary listing on the Hong Kong Stock Exchange.[3] However, in November 2025, Biokin stated it would be delayed due to market conditions.[4]
See also
[edit]References
[edit]- 1 2 3 4 Wen, Molly (24 July 2024). "Sichuan Biokin chases Hong Kong listing after BSM drug deal". Bamboo Works. Retrieved 24 November 2025.
- ↑ Cattan, Nacha (12 December 2023). "Bristol to Pay SystImmune Up to $8.4 Billion in Cancer-Drug Deal". Bloomberg News.
- ↑ Fioretti, Julia (11 July 2024). "Sichuan Biokin Pharma Files for $500 Million Hong Kong IPO". Bloomberg News.
- ↑ Li, Cao (12 November 2025). "Chinese drug developer Biokin postpones Hong Kong listing". South China Morning Post. Retrieved 24 November 2025.
